# EDGAR Filing Document

**Accession Number:** 0001679628
**File Stem:** 0001493152-26-027500
**Filing Date:** 2026-6
**Character Count:** 13331
**Document Hash:** 842c3fa40f23fc350709fe77052853d7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-027500.hdr.sgml**: 20260605

**ACCESSION NUMBER**: 0001493152-26-027500

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260602

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260605

**DATE AS OF CHANGE**: 20260605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JUPITER NEUROSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001679628
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474828381
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41265
- **FILM NUMBER:** 261069612

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 NORTH US HWY 1
- **STREET 2:** SUITE 504
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477
- **BUSINESS PHONE:** (561) 406-6154

**MAIL ADDRESS:**
- **STREET 1:** 1001 NORTH US HWY 1
- **STREET 2:** SUITE 504
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Jupiter Orphan Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20160713

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

June 2, 2026

Date of Report (Date of earliest event reported)

**<u>JUPITER NEUROSCIENCES, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41265** | **47-4828381** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **1001 North US HWY 1, Suite 504, Jupiter, FL** | **33477** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(561) 406-6154</u>**

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | JUNS | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**(e) Compensatory Arrangements of Certain Officers**

The following sets forth certain compensatory arrangements entered into, adopted or modified by Jupiter Neurosciences, Inc. (the "Company") during the period covered by this Current Report.

**<u>Alison Silva</u>**

On June 5, 2026, the Company entered into amendment No. 3 (the "Amendment") to the employment agreement with Alison Silva, dated September 1, 2021, as amended. The Amendment appoints Ms. Silva as the Company's Chief Operating Officer and President and increases Ms. Silva's base salary to $340,200 from $315,000. In connection with the Amendment, on June 2, 2026, the board of directors of the Company (the "Board"), based on the recommendation of the compensation committee of the Board (the "Compensation Committee"), approved a one-time grant of options to purchase up to 600,000 shares of the Company's common stock under the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (the "Plan") to Ms. Silva with an exercise price equal to the closing price of the Company's common stock on the Nasdaq Capital Market on the date of grant to recognize her contributions to the Company. Such option grant vests over three years commencing from September 2, 2026 in equal quarterly installments, subject to the recipient's continued service with the Company through each applicable vesting date.

The foregoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety, by the full text of the Amendment, a copy of which is attached to this Current Report as Exhibit 10.1.

**<u>Director Compensation</u>**

On June 2, 2026, the Compensation Committee approved a grant of stock options to each of the Company's independent non-employee directors to purchase up to 100,000 shares of the Company's common stock under the Plan, with an exercise price per share equal to the closing price of the Company's common stock on the Nasdaq Capital Market on the date of grant. Such option grants vest over three years commencing from September 2, 2026 in equal quarterly installments, subject to the recipient's continued service with the Company through each applicable vesting date.

**<u>Discretionary Bonus Options in Lieu of Cash and Long-Term Incentive Compensation</u>**

On June 2, 2026, the Board, based on the recommendation of the Compensation Committee, approved discretionary bonuses to the following executives in the form of stock options under the Plan in lieu of cash:

---

| | | |
|:---|:---|:---|
| **Executive** | **Title** | **Option Grant** |
| Christer Rosén | Chairman of Board, Chief Executive Officer and Director | 747783 |
| Alison Silva | Chief Operating Officer and President | 427304 |
| Saleem Elmasri | Chief Financial Officer | 325565 |
| Marshall Hayward, Ph.D. | Chief Scientific Officer and Director | 259231 |
| Alexander Rosén | Chief Administrative Officer | 341843 |

---

In addition, the Board, based on the recommendation of the Compensation Committee, approved a one-time grant of options to purchase up to 200,000 shares of the Company's common stock under the Plan to Mr. Elmasri with an exercise price equal to the closing price of the Company's common stock on the Nasdaq Capital Market on the date of grant to recognize his contributions to the Company. Each such grant vests over three years commencing from September 2, 2026 in equal quarterly installments, subject to the recipient's continued service with the Company through each applicable vesting date.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Amendment No. 3 to Executive Employment Agreement, dated as of June 5, 2026, between the Company and Alison Silva.](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **JUPITER NEUROSCIENCES, INC.** | **JUPITER NEUROSCIENCES, INC.** |
| Date: June 5, 2026 | By: | */s/ Christer Rosén* |
|  | Name: | Christer Rosén |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**Amendment No. 3 to Executive Employment Agreement**

Dated as of June 5, 2026

This Amendment No. 3 to Executive Employment Agreement (this "Amendment") dated as of the date first set forth above (the "Amendment Date") is entered into by and between Jupiter Neurosciences, Inc., a Delaware corporation (the "Company"), and Alison Silva (the "Executive"). The Company and Executive may collectively be referred to as the "Parties" and each individually as a "Party".

WHEREAS, the Parties are the parties to that certain Executive Employment Agreement, dated as of September 1, 2021 (the "Original Agreement"), as amended by that certain Amendment to Executive Employment Agreement dated as of September 29, 2021 ("Amendment No. 1"), and that certain Amendment to Executive Employment Agreement dated as of December 18, 2023 ("Amendment No. 2," and together with the Original Agreement and Amendment No. 1, the "Agreement"), and now desire to further amend the Agreement as set forth herein and pursuant to Section 14 of the Original Agreement the Parties may amend the Agreement in writing;

NOW, THEREFORE, in consideration of the promises and of the mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Defined Terms.</u> Defined terms used herein without definition shall have the meanings given in
 the Original Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Amendment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Pursuant
 to Section 14 of the Original Agreement, Section 1(b) of the Original Agreement is hereby
 amended and restated to provide that the Executive shall serve as the Chief Operating Officer
 and President of the Company and shall report to the Chief Executive Officer of the Company.
 The Executive shall have such duties and responsibilities as are consistent with Executive's
 position as Chief Operating Officer and President of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Effective
 as of the Amendment Date, Section 2(a) of the Original Agreement, as amended by Amendment
 No. 2, is hereby further amended to provide that the Executive's annual Base Salary
 shall be $340,200 on an annual basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) All
 references in the Original Agreement to 'President and Chief Business Officer'
 or 'Chief Business Officer' shall be deemed references to 'Chief Operating
 Officer and President' or 'Chief Operating Officer,' respectively.

&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Remainder in Force</u>. Other than as amended herein, the Agreement shall remain in full force and
 effect until terminated in accordance with its terms. Any reference in the Original Agreement
 to the "Agreement" shall now be deemed a reference to the Original Agreement
 as amended by Amendment No. 1, Amendment No. 2 and this Amendment. For the avoidance of doubt,
 all restrictive covenants contained in the Original Agreement shall remain in full force
 and effect and shall apply to the Executive in her capacity as Chief Operating Officer and
 President.

&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 headings in this Amendment are for reference only and shall not affect the interpretation
 of this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) This
 Amendment and the rights and obligations of the Parties shall be governed by and construed
 and enforced in accordance with the laws of the State of Florida without giving effect to
 any choice or conflict of law provision or rule (whether of the State of Florida or any other
 jurisdiction).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) This
 Amendment may be executed in counterparts, each of which shall be deemed an original, but
 all of which together shall be deemed to be one and the same agreement. A signed copy of
 this Amendment delivered by facsimile, e-mail or other means of electronic transmission shall
 be deemed to have the same legal effect as delivery of an original signed copy of this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The
 compensation and other terms set forth in this Amendment have been approved by the Board
 of Directors (or the Compensation Committee thereof) of the Company. Executive acknowledges
 that all compensation payable under the Agreement, as amended hereby, shall be subject to
 the Company's compensation recovery (clawback) policy as in effect from time to time.

 

*[Signatures appear on following page]*

 

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed as of the Amendment Date.

---

| | |
|:---|:---|
| Jupiter Neurosciences, Inc. | Jupiter Neurosciences, Inc. |
| By: | */s/ Christer Rosén* |
| Name: | Christer Rosén |
| Title: | Chief Executive Officer |
| Executive: Alison Silva | Executive: Alison Silva |
| By: | */s/ Alison Silva* |
| Name: | Alison Silva |

---